152 related articles for article (PubMed ID: 7543624)
21. Impaired expression of erythrocyte glycosyl-phosphatidylinositol-anchored membrane CD59 in patients with psoriatic arthritis. Relation to terminal complement pathway activation.
Triolo G; Accardo-Palumbo A; Sallì L; Ciccia F; Ferrante A; Tedesco L; Sallì S; Giardina E; Pappalardo A; Licata G
Clin Exp Rheumatol; 2003; 21(2):225-8. PubMed ID: 12747280
[TBL] [Abstract][Full Text] [Related]
22. Role of CD59 in experimental glomerulonephritis in rats.
Matsuo S; Nishikage H; Yoshida F; Nomura A; Piddlesden SJ; Morgan BP
Kidney Int; 1994 Jul; 46(1):191-200. PubMed ID: 7523753
[TBL] [Abstract][Full Text] [Related]
23. Decreased expression of vascular endothelial growth factor in idiopathic membranous glomerulonephritis: relationships to clinical course.
Honkanen E; von Willebrand E; Koskinen P; Teppo AM; Törnroth T; Ruutu M; Grönhagen-Riska C
Am J Kidney Dis; 2003 Dec; 42(6):1139-48. PubMed ID: 14655184
[TBL] [Abstract][Full Text] [Related]
24. Assessment of soluble adhesion molecules (sICAM-1, sVCAM-1, sELAM-1) and complement cleavage products (sC4d, sC5b-9) in urine. Clinical monitoring of renal allograft recipients.
Bechtel U; Scheuer R; Landgraf R; König A; Feucht HE
Transplantation; 1994 Oct; 58(8):905-11. PubMed ID: 7524208
[TBL] [Abstract][Full Text] [Related]
25. Urinary glycosaminoglycan composition in chronic glomerulonephritis.
De Muro P; Faedda R; Satta A; Finetti D; Masala A; Cigni A; Sanna GM; Cherchi GM
J Nephrol; 2005; 18(2):154-60. PubMed ID: 15931643
[TBL] [Abstract][Full Text] [Related]
26. Protection of gingival epithelium against complement-mediated damage by strong expression of the membrane attack complex inhibitor protectin (CD59).
Rautemaa R; Meri S
J Dent Res; 1996 Jan; 75(1):568-74. PubMed ID: 8655761
[TBL] [Abstract][Full Text] [Related]
27. Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organelles (prostasomes), binds cell membranes, and inhibits complement-mediated lysis.
Rooney IA; Atkinson JP; Krul ES; Schonfeld G; Polakoski K; Saffitz JE; Morgan BP
J Exp Med; 1993 May; 177(5):1409-20. PubMed ID: 7683035
[TBL] [Abstract][Full Text] [Related]
28. Structural study on the glycosyl-phosphatidylinositol anchor and the asparagine-linked sugar chain of a soluble form of CD59 in human urine.
Nakano Y; Noda K; Endo T; Kobata A; Tomita M
Arch Biochem Biophys; 1994 May; 311(1):117-26. PubMed ID: 7514386
[TBL] [Abstract][Full Text] [Related]
29. Recombinant soluble CD59 inhibits reactive haemolysis with complement.
Sugita Y; Ito K; Shiozuka K; Suzuki H; Gushima H; Tomita M; Masuho Y
Immunology; 1994 May; 82(1):34-41. PubMed ID: 7519172
[TBL] [Abstract][Full Text] [Related]
30. Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues.
Meri S; Waldmann H; Lachmann PJ
Lab Invest; 1991 Nov; 65(5):532-7. PubMed ID: 1721667
[TBL] [Abstract][Full Text] [Related]
31. Regulation of CD59 expression on the human endothelial cell line EA.hy 926.
Meri S; Mattila P; Renkonen R
Eur J Immunol; 1993 Oct; 23(10):2511-6. PubMed ID: 7691609
[TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal fluid concentrations of the complement MAC inhibitor CD59 in multiple sclerosis and patients with other neurological disorders.
Roddy J; Clark I; Hazleman BL; Compston DA; Scolding NJ
J Neurol; 1994 Aug; 241(9):557-60. PubMed ID: 7528270
[TBL] [Abstract][Full Text] [Related]
33. Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium.
Väkevä A; Morgan BP; Tikkanen I; Helin K; Laurila P; Meri S
Am J Pathol; 1994 Jun; 144(6):1357-68. PubMed ID: 7515561
[TBL] [Abstract][Full Text] [Related]
34. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
Niehans GA; Cherwitz DL; Staley NA; Knapp DJ; Dalmasso AP
Am J Pathol; 1996 Jul; 149(1):129-42. PubMed ID: 8686736
[TBL] [Abstract][Full Text] [Related]
35. T helper (Th)-cytokines in the urine of patients with primary glomerulonephritis treated with immunosuppressive drugs: Can they predict outcome?
Kalavrizioti D; Gerolymos M; Rodi M; Kalliakmani P; Provatopoulou S; Eleftheriadis T; Mouzaki A; Goumenos DS
Cytokine; 2015 Dec; 76(2):260-269. PubMed ID: 26307557
[TBL] [Abstract][Full Text] [Related]
36. Expression of CD59, a regulator of the membrane attack complex of complement, on human astrocytes.
Gordon DL; Sadlon T; Hefford C; Adrian D
Brain Res Mol Brain Res; 1993 Jun; 18(4):335-8. PubMed ID: 7686996
[TBL] [Abstract][Full Text] [Related]
37. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer.
Jarvis GA; Li J; Hakulinen J; Brady KA; Nordling S; Dahiya R; Meri S
Int J Cancer; 1997 Jun; 71(6):1049-55. PubMed ID: 9185710
[TBL] [Abstract][Full Text] [Related]
38. Acquired resistance of Escherichia coli to complement lysis by binding of glycophosphoinositol-anchored protectin (CD59).
Rautemaa R; Jarvis GA; Marnila P; Meri S
Infect Immun; 1998 May; 66(5):1928-33. PubMed ID: 9573071
[TBL] [Abstract][Full Text] [Related]
39. Complement membrane attack complex and protectin (CD59) in liver allografts during acute rejection.
Lautenschlager I; Höckerstedt K; Meri S
J Hepatol; 1999 Sep; 31(3):537-41. PubMed ID: 10488715
[TBL] [Abstract][Full Text] [Related]
40. The complement-inhibiting protein, protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells.
Rooney IA; Davies A; Griffiths D; Williams JD; Davies M; Meri S; Lachmann PJ; Morgan BP
Clin Exp Immunol; 1991 Feb; 83(2):251-6. PubMed ID: 1704296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
